Phylogica, Genentech extend agreement

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Phylogica Ltd. said Genentech has extended its exclusivity period for the research collaboration and license agreement to discover novel antibiotics utilizing Phylogica’s Phylomer drug discovery platform, including its proprietary cell penetrating peptide discovery technology.

A member of the Roche Group, Phylogica is a public Australian drug discovery company. Genentech is a member of the Roche Group.

YOU MAY BE INTERESTED IN

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

Login